Skip to main content
. 2014 Mar 28;10(3):721. doi: 10.1002/msb.145122

Figure 4. Prediction of antimetabolites for HCC patients.

image

  1. 147 antimetabolites are predicted as potential anticancer drugs through personalized HCC models and 101 of these antimetabolites are effective for inhibiting HCC tumor growth in all six HCC patients. Antimetabolites are also predicted through the use of a generic HCC model that is reconstructed based on the average protein expression data in HCC patients, and 127 potential antimetabolites are identified. Twenty‐six of the antimetabolites predicted based on the generic HCC models are not effective in all six HCC patients.
  2. Distribution of the antimetabolites that are predicted to be effective in number of the personalized HCC models.
  3. 46 of the antimetabolites identified through the use of personalized models cannot be used for inhibition of the HCC tumor in all six HCC patients. The differences between the 46 predicted antimetabolites are shown through the use of personalized and generic HCC models.